• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Antibacterial 7 beta -arylmalonamido-7 alpha -methoxy-3-optionally alkylated thiadiazolylthiomethyl-1-oxadothiacephalosporins of the following formula: <IMAGE> (wherein Ar is 2-thienyl, 3-thienyl, phenyl, p-hydroxyphenyl, p-acyloxyphenyl or p-protected hydroxyphenyl; COB1 and COB2 each is carboxy, protected carboxy or a carboxylate salt; and R is hydrogen or lower alkyl), processes for preparing said compounds, a pharmaceutical or veterinary composition comprising the said compounds and pharmaceutical carrier and a method for treating or preventing human or veterinary infectious diseases comprising administering the said compound.
    公开号:SU812182A3
    申请号:SU782652750
    申请日:1978-08-25
    公开日:1981-03-07
    发明作者:Нарисада Масаюки；Нагата Ватару
    申请人:Сионоги Энд Ко,Лтд (Фирма)；
    IPC主号:
    专利说明:

    1 The invention relates to a process for the preparation of new 7-methoxy-1-oxadethiacephalosporins of the general formula AP-SNSOCN1TG-1n2 $ A-Lc tov where Ar is 3-thienyl, phenyl, p-hydroxyfeNIL or protected as p-hydroxyphenyl ether. owls; and СОВ is a free or protected carboxyl group, provided that the ow and the SOC are both a self-protected carboxyl group, if Ar is a protected p-oxyphenyl, or the cos and the COB are a free carboxyl group , if Ar is p-hydroxyphenyl, R is an atom of water of the genus or methyl, or, in other words, СОВ and СОВ are a free carboxyl group, their salts. These compounds have antibacterial properties. A method is known for producing bactericidal 7-methoxy-1-oxide disiacephalosporins containing in position 3 a 1-methyltetrazol-5-ylthiomethyl substituent which consists in the fact that the corresponding 3-substituted 7-amino-7-methoxy-1-oxacetic tetherfalosporin is acylated to produce arylmemylmethyl . The aim of the invention is to obtain new compounds, expanding the arsenal of substances with antibacterial properties. This goal is achieved based on the well-known reaction of the proposed method for the preparation of compounds of formula (t), XaoraA, in that the compound is generally MH, T, (H) P - "- sJ-cH2 A Aii V where SOC and R have the indicated values, subject to treatment with arylmalonic acid halide of the general formula Ag-CHCOOH (Ml) where SOC and Ar have the indicated values.
    In the solvent medium, while cooling the lump at room temperature and, if necessary, remove the protective GRUP1SH from the protected in the form of simple ether p-oxyphenyl and safe-; a puppy of the carboxyl group of the SOW and SOW groups and, in the case of the SOB and the SOW free carboxyl irpynna, the desired product is isolated in free form or as a salt.
    Typically, the compounds of formula (t) in the case of parenteral administration to the human or animal body are used in the form of salts. The most preferred salts are the sodium or potassium salts of pharmaceutically acceptable organic salts, such as salts of gpocaine or xylokane. When choosing a salt, it is guided by considerations of its safety, solubility, etc.
    Sob Dineni ()) are. strong bactericidal agents against a large number of gram-positive and gram-negative bacteria, as well as valuable medical and veterinary drugs and disinfectants.
    Pharmaceutically acceptable esters of i) compounds of formula (I) are generally suitable for enteric administration. .
    Compounds of formash () are administered orally or parenterally to the human or animal body in order to prevent or treat infectious diseases caused by susceptible bacteria in a daily dose of, for example, 0.05-100 mg / kg body weight. The dosage may be increased or decreased depending on the type of bacteria that caused the disease, the frequency of administration and the condition of the patient.
    The compounds of the formula (O may be used in the form of caitoix in various dosage forms for intestinal and partisanal preparations, widely accepted in pharmacology, or mixed with other coatings or substances or carriers. Fa; 4% cosmetic compositions may be a mixture containing 0.01-99% of a compound of formula (I} with a fake organic carrier — solid material or liquid. The compounds of formula (1) are dissolved, dispersed or suspended in such carrier. They can be in units of
    Compounds oii syjai (1). can usually be introduced into a solution prepared in an ampoule immediately before use. They can be administered in the form of a solution, injection solution, tablets, porridge, capsules, and similar pho {M4 containing dbbaaks or diluents and compiled as a drug.
    Target products can be separated from the reaction mixture by removing the used solvent, unreacted reagents, byproducts and other impurities by conventional methods of evaporation, extraction, adsorption, depletion, washing, chromatography / recrystallization, etc.
    PRI me R 1.
    权利要求:
    Claims (3)
    [1]
    1. Suspension of 375 mg of ot (- methoxybenzyloxyphenyl) -s (-p-methoxy6enzyloxycarbonylacetic acid in
    5 ml of methylene chloride is stirred at a temperature of -15 ° C under a nitrogen atmosphere. 90 µl of triethylamine and 55 µl of oxalyl chloride are added to this suspension (and the reaction mixture is stirred for 1 hour, cooled, mixed with a solution of 228 mg of diphenylmethyl-7-6-methoxy-7) 3-amino-3- (2-methyl-1 , 3,4-thiadiazol-5-yl) -thiomethyl-1-children-1-oxa-3-cephem-4-carboxylate in 5 ml of methylene chloride containing 52 μl of pyridine, stirred for 30 minutes, cooled with ice, and evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with 2N. hydrochloric acid, water, 5% sodium hydrogen carbonate iodine solution, then again with water, dried and concentrated. The residue is purified on a chromatographic column with 20 g of silica gel, resulting in 212 mg of diphenylmethyl-7 / .methoxy-7pcA- (4-p-methoxybenzyl-sci-phenyl) -sl-p-methoxybenzyloxycarbonylacetamido-3- (2-methyl-1 , 3,4-thiadiazol-, -5-yl) -thiomethyl-1-children-1-: Oxa-3-cephem-4-carboxylate with a yield of 52%.
    IR (СНаСО, 1 дА01кс 3405, 3320, 1783, 1717, 1605, 1583 cm-.
    NMR CDCU), tfj, ss S 2.64 S ЗН, 3.44: S ЗН / 2, 3.46 S ЗН / 2, 3.79 S 6Н, 4.18 ABo, (13 HZ) 1Н, 4, 52 ABo, (13 Hz) 1H, 4.52 2H, 4.58 S IH, 4.96 S 2H, 5.02 S IB, 5.12 S 2H.
    [2]
    2. To a solution of 212 mg of the compound obtained according to claim 1, in 2 ml of methylene chloride are added 1 ml of anisole and O, 5 ml of trifluoro-xchroic acid
    O under a nitrogen atmosphere with stirring, the mixture is stirred for 30 minutes at and evaporated under reduced pressure. The residue is washed with ether, resulting in 110 mg
    e 7o1-methoxy-7} - (ot-p-hydroxyphenyl-α-carboxyl-yido) -3- (2-m & l with 1,3,4-tkadyazol-5-yl) -thiomethyl-1-children 1-oxa-3-cephem-4-carboxylic acid with a yield of 94%, so pl. (decomposition), t
    0 IR (KBG) 3380, 2570, 1719, 1613, 1514 cm-.
    UV (CHjOH) ,,, “yu: 5 2; g7 nm (8 14160), 275.5 NML (8 11800). -40.0 ± 1, (with 0.547,
    5) NMR (- NaHCOj), (% Qg: 2.68 S 3H, 3.44 S 3H / 2, 3.50 S 3H / 2, 3.92 ABq (14 Hz) IH, 4.42 ABa ( 14 Hz) IH, 4.45 brs 2H, 5.08 S IH., 6.83 AvB (8 Hz) 2 N, 7.25 A..B2 (8 Hz) 2ll. P p and m ep 2. 1 To a suspension of 268 mg of - (3-thienyl) - oL-DIphenylmutoxycarbonylacetic acid in 4 ml of methylene chloride, 79 µl of triethylamine 49 µl of chlorooxalil are added with cooling ice (R4 and the mixture is stirred for 20 minutes, then mixed with 200mg diphenylmethyl solution -7о6т-methoxy-7 IV-amino-3- (2-methyl-1,3,4-thiadiazol-5-yl) -tisyl 1-children-1-oxa-3-cephem-4-carboxylate in 4m chloride methylene gas containing 46 μl of pyridine, and stirred in those After cooling for 15 minutes, the reaction mixture is diluted with ethyl acetate, washed with 2N hydrochloric acid, water, 5% aqueous solution of sodium hydrogencarbonate and water, dried and concentrated under reduced pressure. a column with a silky gel containing 10% water, resulting in 302 mg of diphenylmethyl-7c1.-methoxy-7p-o1 - (3-thienyl) -ti-diphenylLmethoxycarbonylacetamido 1 | -3- (2-methyl-1, 3,4-thiadiazol-5-yl) -thiomethyl-1-dibiag1-oxa-3-cephem-4-carboxylate with a yield of 93%. .IR (sleep U) max 3400, ЗЗЗЗ, 1782, 1720, 1700, 1625, 1600 CMI Yat (CDCU), "2.62 S ЗН, 3.36 S ЗН, 4, 12 ABft (14 Hz) 1Н, 4 48 (14 Hz) 1H, 4.42 S 2H, 4.6 51H, 4.96 S 1H ,, 6.89 S 1H. ; 2. To a solution of 302 mg of the product obtained according to claim 1, in 4 m of methylene chloride, add 0.5 MP of anisole and 0.4 ml of grichloroacetic acid under and in an atmosphere of nitrogen, and mix the mixture. at the same time for 30 minutes and end edify under reduced pressure. The rest of the prog air is ethereal, resulting in 180 mg of 7c (, - cutoxy 7 | - (- (E-thienyl) - ot-carboxyacetate a1 to-3- (2-methyl-1,3., 4-thiadiasis-5 -yl) -tis ethyl-1-children-1-oxa-3-ceg f "-4-carboxylic acid with an yield of 97% f t pl. above 105 ° C (decomposition) IR (KBg), 0, au: 3270, 2550, 1784, 1714, 1634 cm-1. UV (), L. „j 274 nm (g“, 11050). -36.6 + 1.5 (with “0.524, CHjOH). NMR (DO + NaHC05), fDq55 2.71 S ЗН, 3.46 S J3H / 2, J, 53 S 3H / 2, 3.95 jABcL (13 Hz) IH, 4.47 ABc (13 Hz) 1H | 4.50 brs 2H, 5.12 S IH. Example 3. 1. To a solution of 212 mg of ob-difennmethoxycarbonyl-bC- (3-thienyl) acetic acid in 3 ml of methylene chloride, 79 µl of triethylgene and 49 µl of scs chloride are added After cooling with ice, the mixture is stirred for 20 minutes to obtain the corresponding acid halide. To a solution of 150 mg of diphenylmethyl-7bt-amine-7y-methoxy-3- (1,3,4-thiadiazol72-yl) -thiomethyl-1. -dithi-1-oxa-3-cephem-4-carboxylate in 2 ml of methylene chloride, 36 µl of pyridine and the acid halide prepared using the procedure described above are added. cooling the system with ice with stirring, stirring the mixture for 20 minutes, extracted with ethyl acetate, washed with 2N. hydrochloric acid, in- A 5% strength solution of sodium hydrogen carbonate and water is dried and stained under reduced pressure. The residue is subjected to chromatographic purification of a column with 10 g of silica gel containing 10% water, resulting in half a dose of 235 mg of d.phenylmethyl-7c-mtvoxy-7 I et - (3-tivnil) -o1-diphenylmethoxycarbonyl acetate-3- (1.3, 4-thiadiazol-2-yl) -thiomethyl.-L-Dvthia-l-oxy-3-cepam-4-carboxylate with a yield of 93%. IR (CHCt5) ,, 3390, 3310, 1785, 1720, 1700 cm NMR (sosi), ifj) ssJ 3.42 5 2H, 4.20 (14 Hz) la, 4.47 brs 2H, 4.55 ABcL ( 14 Hz) 1H, 4.87 S 1H, 5.00 S 1H, 6.92 S 2H, 8.92 S IH. . 2. To a solution of 235 mg of the compound obtained according to claim 1, in 1.5 mp of methylene chloride, 1 ml of anisole and 0.5 ml of trifluoroacetic acid are added with and with stirring, the mixture is poached at the same temperature for 1 h and evaporated under reduced pressure. The remainder of the MBdBcUOT EFIRSN4, resulting in 140 mg of 7-6-metxy-7, is obtained. L-fet-carboxy-oC- (3-thienyl) -acetamide-3- (1,3,4-thiadiazol-2-yl) - bistil-1-children-1-oxa-3-cephem-4-carboxylic acid with a yield of 98%, so pl. vvoe. IR (nujol) 5 3275, 1785, 1710 cm-. HMP () 4. 3.47 S ЗН722, 3.52 S ЗН / 2, 4.00d (14 Hz) IH, 4.32 d (14 Hz) IH, 4.50 brs ЗН, 5.10 S IH, 9.43 S IH . n p and M e p 4. 1. To a solution of 234 mg of c-n-tert-butoxyphenyl-ct-tert-butrxycarbonylacetic acid in 2 ml of methylene chloride, 65 µl of triethylamine and 4 µl of oxalne chloride are added and the mixture is stirred for 2 hours at 20 ° C. To this solution is added a solution of 127 mg of tert-butyl-7-6-methoxy-7 fb-amio-3- (1,3,4-thiadiazol-2- "1) -thiomethyl-1-children-1-oxa-3- cephem-4-carboxyl ta in 3 vtn methylene chloride, containing 38 μl of pyridine, and the mixture is stirred for 30 minutes at temperature. Then the reaction mixture is evaporated under reduced pressure. The residue is dissolved in ethyl acetate, 2 n creep. hydrochloric acid, water, 5% aqueous solution of sodium bica bonate and water, dried and concentrated. This residue was purified by chromatography on a column of 20 g of silica gel to give 141 mg of tert-butyl-oC-methoxy-7p - {ot-h-tert-butoxyphenyl-oL-tert. Butoxycarbonylacetamido) -3- ( 1,3,4-thiadiazol-5-yl) -thiethylethyl-dethia-1-oxa-3-cephem-4-carboxylate. The product yield is 64%. IR spectrum: 1,790 cm. AL.SZHS 2. In a solution of 100 mg of tert-butyl-7P) - {of-p-tert-butoxyphenyl-cL-tert. -butoxycarbonylstamido) -7 ot-methoxy-3- (1,3,4-thiadiazol-yl) -thiome of tyl-1-children-1-oxa-3-cephem-4-carboxylate in 1 ml of anisole is added 150 mg gshuminium chloride. After stirring for 60 minutes, the mixture is poured into 2% hydrochloric acid and subjected to extraction with ethyl harsh. The extract solution is washed with hydrochloric acid, an aqueous solution of sodium bicarbonate and water, dried over sodium sulfate, and concentrated to give 49 mg of the same product as in Example 3. Example 1. 1. By analogy with the procedure described in example 4, 208 g of ct-p-methoxymethoxyphenyl-c {, -benzyloxycarbonylacetic acid are treated with 33 μl of casbelic acid chloride and 54 μl of triethylamine at -15 ° C with transmutation for 10 minutes. A solution of 116 mg of benzyl-7 (.-Methoxy-7 (-amino-3- (1,3,4-thiadiazol-5-yl) -thiomethyl-1-children-1-oxa-3-cephem -4-carboxylate in 2 ml of methylene chloride, containing 31 mg of pyridine, and the mixture is stirred for 30 minutes at a temperature of C6, the reaction mixture is concentrated under reduced pressure. The residue is dissolved in ethyl acetate and washed with 2N hydrochloric acid, water, 5% -Hiskf aqueous sodium bicarbonate solution and water, dried and concentrated.The residue is purified by chromatographic treatment in a column with 20 g of silica gel to obtain 168 mg of ben-g from L-7Y-methoxn-7/4 - (O4.-p-methoxymethoxyphenyl-ct-benzyloxycarbonylacetamido) -3- (1,3,4-thiadiazol-5-Sh1) -thiomethyl-1-children-1-oxa-3 -cepheme-4-carboxylate as an oil-like product. The yield of the product is 78%. IR spectrum, 1,785 cm, (lacquer 2. Treatment with 100 mg of benzyl-b-methoxy-7 | b- (L-p-methoxime. toxphenyl-ciL-benzyloxycarbonylacetamido) -3- {1,3,4-thiadiazol-5-yl) -iomethyl-1-children-1-oxa-3-cephem-4-carboxylate by analogy with the example 4, p. 2, 150 mg of chloride / aluminum in 1 ml of anisole for --i 30 min gives 43 mg of the same product as indicated in the example
    [3]
    3. The claims of the method of obtaining 7-methoxy-1-oxadethiacephalosporins of the general formula Ar-CHdenft-if, AR ioB where Ar is 3-thienyl, phenyl, p-hydroxyphenyl or protected as ether p-hydroxyphenyl, SOC and SOC are free or a protected carboxyl group, provided that the owl and the SOC are both a protected carboxyl group, if Ar is protected as the p-hydroxyphenyl ether, or the SOC and SOC are both a free carboxyl group, if Ar is p-hydroxyphenyl , R is a hydrogen atom or methyl, or when SOW and SOW s &amp; carbo The group, their salts, o and t and the fact that the compound of the general formula;, x8D - $ s where the symbols owl and R have the indicated meanings, is subjected to interaction with arymalmalonic acid Gsshoid anhydride of the general formula where SOW and Ar have the indicated meanings, in the medium of a solvent, at cooling or at room temperature and, if necessary, protect groups from protected in the form of ether p-hydroxyphenyl and protect 81218210
    . .t
    valuable carboxyl group of SOW and sources of information
    SOW and in the case when SOW and BOB are taken into account during the examination
    kgfboxyl group is free, you are 1..Patent of the USSR by application,
    the product is divided into freer No. 246.4302 / 23-04, cl. C 07 D 498/04
    in the form of salt in the form of salt. 1976.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU812182A3|1981-03-07|Method of preparing 7-methoxy-1-oxadethiacephalosporins or their salts
    SU820659A3|1981-04-07|Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers |
    CN108516958B|2020-07-17|Fused ring derivative, preparation method, intermediate, pharmaceutical composition and application thereof
    DK144763B|1982-06-01|ANALOGY PROCEDURE FOR PREPARING CEPHALOSPORINE DERIVATIVES
    KR20040091698A|2004-10-28|Novel florfenicol-type antibiotics
    PT93639A|1990-11-20|METHOD FOR THE PREPARATION OF 5-ALKYLQUINOLONOCARBOXYL ACID ACIDS
    JPH068278B2|1994-02-02|Pluromutilin derivative, production method and use thereof
    SU845789A3|1981-07-07|Method of preparing d-7-/alpha-|-alpha-|-acetamido/-3-| thiomethyl-3-cephem-4-carboxylic acid
    DD282691A5|1990-09-19|PROCESS FOR THE PREPARATION OF CEPHALOSPORIN
    US4496578A|1985-01-29|Antihypertensive sulfur-containing compounds
    US5147883A|1992-09-15|Acylbenzoxazolinones compounds
    US3948913A|1976-04-06|New 5-nitrofuryl derivatives
    IL114989A|1998-09-24|Open e-ring camptothecin derivatives preparation thereof and antitumor compositions containing them
    US4044130A|1977-08-23|Compositions for the control of microorganisms
    EP0592664A1|1994-04-20|Novel diphenylthyazole derivative
    WO2003000681A1|2003-01-03|Antibacterial having quinolinecarboxamide skeleton
    CA2881958C|2019-08-27|Pharmaceutical formulations containing 3-| amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation
    GB1596813A|1981-09-03|Benzylpyrimidines process for their production and pharmaceutical preparations containing the same
    SU869560A3|1981-09-30|Method of producing substituted 7-|-3-chloro-3-cephem-4-carboxalic acids
    JP2003521476A|2003-07-15|Thiol derivative, metallo-β-lactamase inhibitor
    US3914379A|1975-10-21|Substituted | hydrazines with antibacterial properties
    JP6890865B1|2021-06-18|Cyclic amide compounds for the treatment of rabies and methods thereof
    US3522252A|1970-07-28|Basic esters of 5-alkanoylamino-3-|isoxazole - 4 - carboxylic acid
    JPH1171336A|1999-03-16|Amide derivative
    US3324003A|1967-06-06|Method of controlling growth of bacteria using 4-methyl-1-benzo[f]quinolone-2-carboxylic acid
    同族专利:
    公开号 | 公开日
    GR70260B|1982-09-02|
    FI782586A|1979-02-26|
    YU43999B|1990-02-28|
    DD137230A5|1979-08-22|
    MX5328E|1983-06-22|
    IE47630B1|1984-05-16|
    FI65432C|1984-05-10|
    RO75070A|1980-10-30|
    CS203927B2|1981-03-31|
    PL110656B1|1980-07-31|
    ATA620378A|1980-07-15|
    GB1576796A|1980-10-15|
    FI65432B|1984-01-31|
    DE2837264C2|1991-06-13|
    PH17508A|1984-09-07|
    CA1101417A|1981-05-19|
    BE869955A|1978-12-18|
    DK372878A|1979-02-26|
    AU517618B2|1981-08-13|
    ZA784753B|1979-08-29|
    AU3923878A|1980-02-28|
    PT68434A|1978-09-01|
    YU202878A|1982-10-31|
    NL190554C|1994-04-18|
    AT361121B|1981-02-25|
    IE781703L|1979-02-25|
    IT1118098B|1986-02-24|
    IT7868975D0|1978-08-24|
    DE2837264A1|1979-03-01|
    BG34338A3|1983-08-15|
    NO782866L|1979-02-27|
    NZ188173A|1981-05-15|
    SE7808950L|1979-02-26|
    JPS5436288A|1979-03-16|
    SE452010B|1987-11-09|
    NL190554B|1993-11-16|
    HU177900B|1982-01-28|
    CH637396A5|1983-07-29|
    FR2401165A1|1979-03-23|
    JPS609718B2|1985-03-12|
    PL209215A1|1979-06-04|
    IL55429D0|1978-10-31|
    NL7808802A|1979-02-27|
    ES472817A1|1979-02-16|
    US4201782A|1980-05-06|
    AR220539A1|1980-11-14|
    FR2401165B1|1982-06-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    NL178005C|1972-11-06|1986-01-02|Merck & Co Inc|METHOD FOR PREPARING A PHARMACEUTICAL PREPARATION WITH ANTIBACTERIAL ACTION, AND METHOD FOR PREPARING A CEPHALOSPORINE ANTIBIOTIC.|
    US4031083A|1975-10-24|1977-06-21|Yeda Research And Development Co., Ltd.|Cephalosporin antibiotics|
    US4045438A|1975-10-24|1977-08-30|Yeda Research And Development Co. Ltd.|Cephalosporin antibiotics|
    FR2361114B1|1975-11-12|1982-09-17|Shionogi & Co|
    CA1085392A|1976-03-25|1980-09-09|Masayuki Narisada|Arylmalonamido-1-oxadethiacephalosporins|
    JP5265292B2|2008-10-06|2013-08-14|イビデングリーンテック株式会社|Tree planting structure and planting method|US4259485A|1979-04-24|1981-03-31|Eli Lilly And Company|Crystallization process|
    FR2494279B1|1980-11-20|1983-02-04|Rhone Poulenc Sante|
    EP0112049B1|1982-12-14|1987-09-09|Beecham Group Plc|Process for the preparation of beta-lactam compounds|
    JPS60123490A|1983-12-07|1985-07-02|Shionogi & Co Ltd|Malonyloxacephem carboxylic acid derivative|
    US6013835A|1995-06-07|2000-01-11|Hfm International, Inc.|Method and apparatus for preparing purified terephthalic acid|
    US6197794B1|1998-01-08|2001-03-06|Celltech Therapeutics Limited|Phenylalanine derivatives|
    US6329372B1|1998-01-27|2001-12-11|Celltech Therapeutics Limited|Phenylalanine derivatives|
    ES2226413T3|1998-02-26|2005-03-16|Celltech Therapeutics Limited|PHENYLALANINE DERIVATIVES AS INTEGRIN ALFA-4 INHIBITORS.|
    GB9805655D0|1998-03-16|1998-05-13|Celltech Therapeutics Ltd|Chemical compounds|
    US6521626B1|1998-03-24|2003-02-18|Celltech R&D Limited|Thiocarboxamide derivatives|
    GB9811159D0|1998-05-22|1998-07-22|Celltech Therapeutics Ltd|Chemical compounds|
    GB9811969D0|1998-06-03|1998-07-29|Celltech Therapeutics Ltd|Chemical compounds|
    GB9812088D0|1998-06-05|1998-08-05|Celltech Therapeutics Ltd|Chemical compounds|
    GB9814414D0|1998-07-03|1998-09-02|Celltech Therapeutics Ltd|Chemical compounds|
    GB9821061D0|1998-09-28|1998-11-18|Celltech Therapeutics Ltd|Chemical compounds|
    GB9821222D0|1998-09-30|1998-11-25|Celltech Therapeutics Ltd|Chemical compounds|
    GB9821406D0|1998-10-01|1998-11-25|Celltech Therapeutics Ltd|Chemical compounds|
    GB9825652D0|1998-11-23|1999-01-13|Celltech Therapeutics Ltd|Chemical compounds|
    US6518283B1|1999-05-28|2003-02-11|Celltech R&D Limited|Squaric acid derivatives|
    US6534513B1|1999-09-29|2003-03-18|Celltech R&D Limited|Phenylalkanoic acid derivatives|
    US6455539B2|1999-12-23|2002-09-24|Celltech R&D Limited|Squaric acid derivates|
    AU4855301A|2000-04-17|2001-10-30|Celltech R And D Ltd|Enamine derivatives|
    US6403608B1|2000-05-30|2002-06-11|Celltech R&D, Ltd.|3-Substituted isoquinolin-1-yl derivatives|
    US6545013B2|2000-05-30|2003-04-08|Celltech R&D Limited|2,7-naphthyridine derivatives|
    US6740654B2|2000-07-07|2004-05-25|Celltech R & D Limited|Squaric acid derivatives|
    US6649756B2|2000-07-13|2003-11-18|Wyeth, Five Giralda Farms|Process improvement in the preparation of -3-[[-2-[[[-2-amino-3-methyl-1-oxobutyl]amino]methyl]tetrahydro-3-furanyl]thio]-6-[-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid|
    AU7572401A|2000-08-02|2002-02-13|Celltech R And D Ltd|3-substituted isoquinolin-1-yl derivatives|
    CN102827191B|2012-09-24|2015-03-11|浙江东邦药业有限公司|Method for preparing oxygen cephalosporin compound|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP52102261A|JPS609718B2|1977-08-25|1977-08-25|
    [返回顶部]